Altitude sickness laboratory findings: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 5: Line 5:
Please help WikiDoc by adding more content here.  It's easy!  Click  [[Help:How_to_Edit_a_Page|here]]  to learn about editing.
Please help WikiDoc by adding more content here.  It's easy!  Click  [[Help:How_to_Edit_a_Page|here]]  to learn about editing.
==Overview==
==Overview==
Chronic mountain sickness (CMS) is characterised by [[polycythemia]] (increased [[hematocrit]]) and [[hypoxemia]] which both decrease on descent from altitude.  CMS is believed to arise because of an excessive production of red blood cells, which increases the oxygen carrying capacity of the blood but may cause increased blood viscosity and uneven blood flow through the lungs ([[V/Q mismatch]]). However, CMS is also considered an adaptation of pulmonary and heart disease to life under chronic hypoxia at altitude<ref name="pmid17072074">{{cite journal| author=Zubieta-Castillo G, Zubieta-Calleja GR, Zubieta-Calleja L| title=Chronic mountain sickness: the reaction of physical disorders to chronic hypoxia. | journal=J Physiol Pharmacol | year= 2006 | volume= 57 Suppl 4 | issue=  | pages= 431-42 | pmid=17072074 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17072074  }} </ref>.
Chronic mountain sickness (CMS) is characterised by [[polycythemia]] (increased [[hematocrit]]) and [[hypoxemia]] which both decrease on descent from altitude.  CMS is believed to arise because of an excessive production of red blood cells, which increases the oxygen carrying capacity of the blood but may cause increased blood viscosity and uneven blood flow through the lungs ([[V/Q mismatch]]). However, CMS is also considered an adaptation of pulmonary and heart disease to life under chronic hypoxia at altitude<ref name="pmid17072074">{{cite journal| author=Zubieta-Castillo G, Zubieta-Calleja GR, Zubieta-Calleja L| title=Chronic mountain sickness: the reaction of physical disorders to chronic hypoxia. | journal=J Physiol Pharmacol | year= 2006 | volume= 57 Suppl 4 | issue=  | pages= 431-42 | pmid=17072074 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17072074  }} </ref>. [[Clinical]] diagnosis by laboratory indicators have ranges of: [[Hemoglobin|Hb]] > 200 g/L, [[Hematocrit|Hct]] >65%, and arterial oxygen saturation (SaO2) <85% in both genders.<ref name="pmid20586602">{{cite journal| author=West JB| title=English translation of "Nomenclature, classification, and diagnostic criteria of high altitude disease in China". | journal=High Alt Med Biol | year= 2010 | volume= 11 | issue= 2 | pages= 169-72 | pmid=20586602 | doi=10.1089/ham.2010.1014 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20586602  }} </ref>


==References==
==References==

Revision as of 14:27, 4 February 2013

Altitude sickness Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Altitude Sickness from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Altitude sickness laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Altitude sickness laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Altitude sickness laboratory findings

CDC on Altitude sickness laboratory findings

Altitude sickness laboratory findings in the news

Blogs on Altitude sickness laboratory findings

Directions to Hospitals Treating Altitude sickness

Risk calculators and risk factors for Altitude sickness laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Overview

Chronic mountain sickness (CMS) is characterised by polycythemia (increased hematocrit) and hypoxemia which both decrease on descent from altitude. CMS is believed to arise because of an excessive production of red blood cells, which increases the oxygen carrying capacity of the blood but may cause increased blood viscosity and uneven blood flow through the lungs (V/Q mismatch). However, CMS is also considered an adaptation of pulmonary and heart disease to life under chronic hypoxia at altitude[1]. Clinical diagnosis by laboratory indicators have ranges of: Hb > 200 g/L, Hct >65%, and arterial oxygen saturation (SaO2) <85% in both genders.[2]

References

  1. Zubieta-Castillo G, Zubieta-Calleja GR, Zubieta-Calleja L (2006). "Chronic mountain sickness: the reaction of physical disorders to chronic hypoxia". J Physiol Pharmacol. 57 Suppl 4: 431–42. PMID 17072074.
  2. West JB (2010). "English translation of "Nomenclature, classification, and diagnostic criteria of high altitude disease in China"". High Alt Med Biol. 11 (2): 169–72. doi:10.1089/ham.2010.1014. PMID 20586602.

Template:WH Template:WS